Accordingly, we hypothesized that: (1) S100B concentrations in pediatric patients with ADHD should differ from controls; and (2) variations in S100B levels should accompany the clinical response of ADHD patients with a triple therapy consisting of MPH, aMT and ω-3 PUFAs. The gene discussed is S100B; the disease is attention deficit-hyperactivity disorder.